Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2025 04:32 ET | Source: Research and Markets

Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024-2030: Advances in Next-Gen Immunotherapies, AI, and Biomarker-Driven Personalization are Driving Transformational Growth

Dublin, Sept. 22, 2025 (GLOBE NEWSWIRE) -- The "Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024-2030" report has been added to ResearchAndMarkets.com's offering. The revenue...
September 08, 2025 10:39 ET | Source: Research and Markets

Trends & Strategies in the $54 Billion PD-1 & PD-L1 Inhibitors Market 2025: Industry Revenues Will More Than Double by 2030

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "PD-1 & PD-L1 Inhibitors Market Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The PD-1 & PD-L1 Inhibitors...
September 02, 2025 06:06 ET | Source: Research and Markets

Immuno-oncology Clinical Trials Markets and Competition Report 2025-2030: Analysis by Therapy Type, Trial Phase, Indication, Sponsor Type, Trial Type, Patient Enrollment and Region

Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The "Immuno-oncology Clinical Trials Market by Therapy Type (Adoptive Cell Therapies, Cancer Vaccines, Checkpoint Inhibitors), Trial Phase (Phase I, Phase...
August 28, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
July 30, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
July 09, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
June 30, 2025 04:03 ET | Source: Research and Markets

Immuno-oncology: Diagnostics Pave the Path to Therapeutic Success

Dublin, June 30, 2025 (GLOBE NEWSWIRE) -- The "Market Forecasts for Immuno-Oncology Diagnostics Including Executive/Consultant Guides and Customized Forecasting/Analysis" report has been added to ...
June 24, 2025 08:33 ET | Source: Research and Markets

Interleukin-2 Market Analysis and Forecast, 2025-2035 | Engineered IL-2 Therapies Lead Innovations in Immunotherapy

Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Interleukin-2 Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's...
May 27, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
May 22, 2025 17:05 ET | Source: Candel Therapeutics

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...